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ScienceDirectThe importance of Cytochrome P450-catalyzed modifications
of natural products produced by non-ribosomal peptide
synthetase machineries is most apparent during glycopeptide
antibiotic biosynthesis: specifically, the formation of essential
amino acid side chains crosslinks in the peptide backbone of
these clinically relevant antibiotics. These cyclization reactions
take place whilst the peptide substrate remains bound to the
non-ribosomal peptide synthetase in a process mediated by
a conserved domain of previously unknown function — the
X-domain. This review addresses recent advances in
understanding P450 recruitment to non-ribosomal peptide
synthetase-bound substrates and highlights the importance of
both carrier proteins and the X-domain in different P450-
catalyzed reactions.
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The role of Cytochrome P450s in glycopeptide
antibiotic biosynthesis
The use of glycopeptide antibiotics (GPAs) as antibiotics
of last resort against methicillin-resistant Staphylococcus
aureus (MRSA) together with their long clinical lifetimeCurrent Opinion in Structural Biology 2016, 41:46–53 has made these highly important compounds for human
health [1,2]. From a structural viewpoint GPAs have an
intriguingly complex architecture, specifically their highly
crosslinked state: GPAs possess three or four biaryl and
biaryl-ether cross-links between the side chains of aromatic
amino acids present in their heptapeptide backbone
(Figure 1) [1,2]. These cross-links lead to the characteristic
three-dimensional cup shape of the GPA aglycone. This
structure is essential for their activity, as it confers binding
towards the Lys-D-Ala-D-Ala motif present in various stages
of the bacterial cell wall biosynthesis, for example, Lipid II
and its precursors, via five hydrogen bonds [2,3]. Previously
it has been shown that GPAs are assembled by a non-
ribosomal peptide synthetase (NRPS) [4]. Gene inacti-
vation studies revealed that P450 monooxygenase enzymes
install the crosslinks present in both balhimycin [5,6] and
in the teicoplanin-type GPA A47934 [7] with a strict order
of cyclization steps. This was determined by inactivation
of each of the P450s, which resulted in the accumulation of
intermediates at a distinct stage of side-chain cyclization
due to stalling of the biosynthetic machinery. Hence, for
the type-I GPA balhimycin it could be shown that the first
ring-system to be formed is the C-O-D diaryl ether ring
catalyzed by OxyB, followed by the OxyA-catalyzed D-O-E
diaryl ether ring-system and finally the biaryl AB system,
which is catalyzed by OxyC (Figure 1) [5,6]. Similar
experiments were performed for the teicoplanin-like
GPA A47934, through which the order of cyclizations C-
O-D ! F-O-G (performed by the enzyme OxyE) ! D-O-
E ! AB could be established (Figure 1) [7]. Further-
more, these results indicated that P450 monooxygenases
would function in close interaction with the NRPS assem-
bly line [8]. This knowledge set the stage for subsequent
experiments on the in vitro reconstitution of the vancomy-
cin P450 monooxygenase OxyB with peptide substrates
[9–11,12,13]. Here, the conversion of linear hexa-peptide
peptidyl carrier protein and hepta-peptide peptidyl carrier
protein (PCP) thioesters could be achieved, whilst linear
heptapeptides not presented on a PCP domain were not
suitable substrates [11,12].
PCP-driven P450 recruitment
Amino acid hydroxylation
Along with the cyclization reactions performed by P450s in
GPA biosynthesis, some GPAs require b-R-hydroxytyro-
sine as a precursor for NRPS-catalyzed peptide assembly
[4,14,15]. This hydroxylation is P450 catalyzed andwww.sciencedirect.com
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Figure 1
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Structural overview of glycopeptide antibiotics. (a) Order of cyclization reactions and enzymes involved during the biosynthesis of A47934. Altered
GPA structures of (b) bromobalhimycin, produced by supplementation of the media with bromine salts, and (c) an octapeptide, produced by an
engineered NRPS Amycolatopsis balhimycina mutant.involves a separate NRPS module that generates aminoa-
cyl-PCP (Tyr-PCP) substrate for this P450, OxyD [4].
The structure of OxyD, whilst conforming to the canonical
P450 fold, displays some unusual features: in particular a
resolved B-C loop, which is typically unfolded in the
absence of substrate [16]. Biochemical data showing that
the PCP-domain was the main source of OxyD selectivity
led to the hypothesis that this structural arrangement was
generating the required PCP-binding surface to allow
complex formation (Figure 2) [16]. Sequence alignments
with other aminoacyl-PCP oxidizing P450s confirmed that
many residues in this hypothesized interaction surface
were highly conserved, supporting this hypothesis [16].
Structural comparison of a related P450 responsible for
aminoacyl-PCP oxidation from skyllamycin biosynthesis
showed a highly similar tertiary structure to OxyD in spite
of the low identities of the PCP binding partners (Figure 2)
[17]. In contrast to OxyD, P450sky selectively oxidizes
specific PCP-bound AAs within the main NRPS machin-
ery: despite this major mechanistic difference, the PCP-
binding interface remains essentially the same as for OxyD
[17,18]. Structural characterization of P450sky in trapped
complex with a skyllamycin PCP-domain was a furtherwww.sciencedirect.com important step into understanding how such PCP binding
is mediated (Figure 2), which revealed a different CP
binding site to that of the only other example of such a
complex solved to date (the P450BioI-ACP complex)
[19,20]. In contrast to the P450BioI-ACP complex, the
majority of interactions are hydrophobic in nature, with
hydrophobic pockets from both PCP and P450 serving to
bind complementary residues from the protein partner
[19,20]. Also, as the only PCP-bound P450 complex
solved to date, this structure has also proved highly valu-
able to model PCP binding to GPA cyclization P450s.
Peptide cyclization
OxyBvan is the initial peptide cyclization enzyme from
vancomycin biosynthesis and was the first structurally
and functionally characterized GPA cyclization enzyme
[12,21]. In the structure of OxyBvan, the active site is
highly solvent exposed as the F and G helices are held
open above the active site; the structure is even more open
than those of the aminoacyl-PCP oxidases [21]. Flexible
loops around the active site were not resolved in the
structure of OxyBvan and thus the question of peptide
orientation is difficult to assess, with peptide soaking
experiments not successful to date. Following on from inCurrent Opinion in Structural Biology 2016, 41:46–53
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Structures of the P450s OxyD (a) and P450sky (b) involved in hydroxylation of PCP-bound amino acids, with residues postulated to be involved in
the PCP-binding interface shown in color; structure of the complex of an inhibitor bound PCP domain and P450sky showing the positioning of the
PCP domain (c) and a close up view focusing on the major hydrophobic interaction interface between the two proteins (d).vivo experiments, PCP substrates were tested and shown to
be greatly preferred substrates for OxyBvan over free pep-
tides [9–11,12]: this established the paradigm that GPA
cyclization P450 catalysts accept peptidyl-PCP substrates,
although work on other systems combined with the lack of
progress in establishing subsequent steps in peptide cycli-
zation were a clue that our understanding of peptide
cyclization in GPA biosynthesis was not complete [22].
X-domain driven recruitment
The X-domain
A unique feature of the terminal module of all GPA
producing systems is an additional domain between theCurrent Opinion in Structural Biology 2016, 41:46–53 terminal PCP and Te-domains, known as the X-domain
[1,23]. Phylogenetic analysis showed that the X-domain is
related to an LCL type condensation domain, although no
function in peptide synthesis could be assigned [24].
Furthermore, the conserved catalytic motif of C-domains
is altered from HHxxxDG to HRxxxDD, likely render-
ing this domain inactive. The structure of the X-domain
demonstrates the effects of these mutations [25], whilst
confirming that the X-domain indeed conforms to a
C-domain type fold (Figure 3): this is described by
two structurally similar subdomains that belong to the
chloramphenicol-acetyltransferase superfamily fold con-
nected at the bottom of their V-shaped arrangement. Inwww.sciencedirect.com
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Structure of the X-domain from teicoplanin biosynthesis conforms to that of a condensation domain (a); a comparison of the structures of OxyB
from teicoplanin biosynthesis (b) both isolated (green) and in complex with the X-domain (gray with altered regions shown in magenta); structure
of the complex of the X-domain and OxyB from teicoplanin biosynthesis (c); and crucial interactions between the X-domain and the aspartate
residues of the OxyB PRDD motif (d).comparison to other C-domain and E-domain structures
[26,27,28,29,30,31], at least five additional residues ex-
tend this connection, whilst contact between subdomains
is established by two crossover regions originating from
the C-terminal subdomain: region I (known as the floor)
and II (known as the latch). The altered active site of the
X-domain is located in the V-shaped cleft, with residues
R141 and D146 blocking the expected binding site of
the PCP donor-Ppant arm during peptide bond formation.
In addition, R141 forms a salt bridge to E391 in the
C-terminal subdomain, which closes off the active site.
Comparison to the C-domain of the AB3403 NRPS ter-
minal module — in which the C-domain interacts with
the holo-PCP domain — demonstrates that R23 fromwww.sciencedirect.com a1-helix of the X-domain also would block the entry of
the Ppant-linker from the acceptor PCP side [26]. Struc-
tural characterization therefore demonstrates that the
X-domain is unable to play a role in peptide elongation:
thus, the role of this conserved domain continued to be a
mystery.
P450 recruitment mediated by the X-domain
Once binding interactions between GPA cyclizing P450s
and the X-domain were revealed [25], a potential role
for the X-domain in peptide cyclization became clear.
Activity assays indicated that all Oxy enzymes tested —
except OxyBvan — required the X-domain to catalyze
even moderate levels of peptidyl-PCP cyclization [25]:Current Opinion in Structural Biology 2016, 41:46–53
50 Catalysis and regulationcrucially, this included the first reports of GPA peptide
bicyclization catalyzed by an OxyA homologue [25,32,
33]. OxyBvan is clearly an outlier in GPA cyclizing
P450s: recent results have shown that although OxyBvan
can catalyze peptide crosslinking when substrates are
presented solely by a PCP-domain, the binding affinity
and reaction velocity is dramatically increased in the
presence of the X-domain [11,13,25,32,33,34]. Whilst
the role of the X-domain is likely conserved in vivo, the
properties of OxyBvan make it an important target for use
as an in vitro catalyst.
The nature of the P450/X-domain interaction was identi-
fied once a structure of OxyB in complex with the X-
domain (both from the teicoplanin system) was resolved
(Figure 3) [22,25]. This structure demonstrated that
hydrogen bonding and salt bridges dominate the interac-
tion between the proteins, and that only minor changes
occur to their structures in complex (RMSD 0.9 A˚ — X-
domain alone, 1.1 A˚ — OxyBtei alone). OxyBtei binds to
the X-domain via residues in the F-, G-, D- and E-helices,
thus presenting its active site towards the donor side of
the X-domain. This orientation leaves space for the
peptidyl-PCP substrate, which would be located at the
X-domain donor side due to its position N-terminal of the
X-domain within the NRPS module.
The X-domain interaction interface involves both cross-
over regions between subdomains as well as the a-4 helix
and subsequent loop region. To date, only X-domain
mutants with substitutions in the loop region (R167A,
R171A) have been shown to be essential for both P450
interaction and peptide crosslinking (Figure 3) [25,
33]. This region interacts with the PRDD motif found
at the N-terminal part of the OxyBtei F-helix; such a motif
is also present in the same position in other structurally
characterized Oxy enzymes [21,35–38], which is con-
served amongst the GPA crosslinking P450s and appears
to be a fingerprint for X-domain mediated recruitment.
Comparison of the structure of OxyBtei isolated and in
complex with the X-domain shows that the main changes
in the P450 are located in the F-G helices, which move
slightly down towards the I-helix as a consequence of X-
domain binding (Figure 3) [22,25]. Similar to the Oxy-
Btei structure, the majority of the B-C-region involved in
substrate binding remains unresolved: this serves to dem-
onstrate that the Oxy/X-domain complex is a recruitment
complex and not a substrate-bound complex, which
would require the presence of peptidyl-PCP. Although a
PCP/Oxy structure has not yet been achieved, the OxyB/
X-domain complex combined with the PCP/P450sky
structure allows a model of the expected PCP-domain
position for the GPA crosslinking P450s to be generated
[25]. However, alterations in this model for different
GPA crosslinking P450s are to be expected due to the
different positions of the crosslinks that these P450sCurrent Opinion in Structural Biology 2016, 41:46–53 introduce into the peptide. The recent structure of Oxy-
Atei also indicated that the active site of these P450s can
vary significantly between the different catalysts, with
OxyA displaying far more hydrophilic active site environ-
ments to those of OxyB/C (Figure 4) [21,22,35,37].
Why an X-domain?
In GPA biosynthesis, the X-domain efficiently connects
NRPS-catalyzed peptide assembly with peptide modifi-
cation by up to four tailoring enzymes in trans, all of which
must occur prior to cleavage of the peptide from the
NRPS machinery. In this context, the conserved ‘PRDD’
motif in the F-helix of all GPA crosslinking P450 enzymes
but absent in other related P450s, for example, OxyD,
may function as a preselection motif during X-domain
recruitment that improves the efficiency of the peptide
modification process. In contrast to other P450 enzymes
with PCP-bound substrates, the GPA crosslinking cas-
cade requires the efficient selection of the peptide sub-
strate on the same PCP-domain by multiple, highly
related P450s. Recent results indicate that whilst GPA
crosslinking state is selected for by the P450s, the X-
domain provides the platform for a constant shuffling of
the GPA cyclization P450s, which appears to maintain a
high enough rate of peptide cyclization so as not to impede
peptide biosynthesis by the NRPS [33]. Analysis of GPA
terminal modules indicate that the X-domain was likely to
have been a C-domain of the subsequent module in the
ancestor NRPS to that producing GPAs [24,39], which has
evolved into a P450 recruitment platform for GPAs (an
intact, accessible C-domain active site could both inhibit
P450 binding and cause peptide hydrolysis from the PCP-
domain; this suggests the X-domain active site alterations
are highly important). As no other NRPS systems have
been reported to contain an X-domain, it appears to be an
essential part of the unique GPA cyclization process in
coordinating multiple trans interacting proteins towards
one PCP-bound peptide substrate.
Structural implications for the role of GPA
P450s in vivo
Previously, attempts were made to alter the structure of the
GPA aglycones via biosynthesis (Figure 1): this included
the replacement of chlorine substituents with bromine by
precursor-directed biosynthesis [40] or the feeding of
fluorinated b-hydroxytyrosines and various phenylglycines
to GPA mutant strains employing mutasynthesis [41,42].
Gene inactivation experiments also afforded GPA-like
compounds with distorted aromatic side-chain bridging:
such compounds lost antibacterial activity [8]. Finally,
manipulation of the balhimycin NRPS from a heptamod-
ular to an octamodular assembly line by module insertion
[43] was able to successfully generate an octapeptide:
however, concomitantly the P450 monooxygenase proces-
sing was almost completely abolished. Furthermore, while
the efforts to synthesize precursor compounds and to
reprogram the biosynthesis were enormous, in many caseswww.sciencedirect.com
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Figure 4
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Structural comparisons of the amino acids in the vicinity of the active site heme moieties of OxyBtei (green), OxyAtei (red), OxyEtei (blue) and
OxyCvan (purple), revealing significant differences between these P450s.a significant drop in yields of the corresponding GPAs was
observed. The structural findings on the X-domain as a
platform for GPA cross-linking by P450s have shown that
NRPS processing is a complex process requiring a sophis-
ticated interplay between enzyme domains [25]. A future
goal, that is, reprogramming of the biosynthesis in order
to generate new GPA backbones, will require a deeper
understanding of the interaction and interplay of NRPS
domains. Alternatively, restoring the NRPS-independent
oxidative power of P450 monooxygenases from NRPS
could bring researchers much closer to generating new
glycopeptide antibiotics.
Conclusions
The structural characterization of the Cytochrome P450
enzymes responsible for GPA cyclization and related
processes has greatly improved our understanding ofwww.sciencedirect.com how the protein-bound substrates of these P450s are
selected and the role that these protein-protein interac-
tions play in this process. The characterization of sub-
strate complexes of these P450s is now a high priority, as
this will not only illuminate the mechanism of these
enzymes but will also reveal the origin of their substrate
specificity: this information will be vital to the future
success of reprogramming efforts to produce novel GPAs.
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